Which has higher valuation and earnings, QTTB or MNOV?

Q32 Bio has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 5.10 $29.82M $2.66 6.08 MediciNova $410K 156.06 -$12M -$0.23 N/A

Is QTTB or MNOV more profitable?

Q32 Bio has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. Q32 Bio's return on equity of 149.23% beat MediciNova's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% MediciNova -1,962.98% -27.28% -25.24%

Does the media prefer QTTB or MNOV?

In the previous week, Q32 Bio had 3 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Q32 Bio and 1 mentions for MediciNova. Q32 Bio's average media sentiment score of 0.40 beat MediciNova's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NAGE or MNOV?

In the previous week, Niagen Bioscience had 6 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Niagen Bioscience and 1 mentions for MediciNova. Niagen Bioscience's average media sentiment score of 0.54 beat MediciNova's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MNOV or ARTV?

In the previous week, Artiva Biotherapeutics had 6 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 1 mentions for MediciNova. Artiva Biotherapeutics' average media sentiment score of 1.78 beat MediciNova's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MGNX or MNOV more profitable?

MacroGenics has a net margin of -44.79% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% MediciNova -1,962.98% -27.28% -25.24%

Does the media prefer MGNX or MNOV?

In the previous week, MacroGenics had 1 more articles in the media than MediciNova. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for MediciNova. MacroGenics' average media sentiment score of 0.67 beat MediciNova's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FULC or MNOV?

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 1 mentions for MediciNova. Fulcrum Therapeutics' average media sentiment score of 0.09 beat MediciNova's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MediciNova (MNOV) Competitors

$1.30 -0.03 (-2.26%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.32 +0.01 (+1.15%)

As of 08/4/2026 04:35 PM Eastern

Compare

MNOV vs. QTTB, NAGE, ARTV, MGNX, and FULC

Should you buy MediciNova stock or one of its competitors? MarketBeat compares MediciNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediciNova include Q32 Bio (QTTB), Niagen Bioscience (NAGE), Artiva Biotherapeutics (ARTV), MacroGenics (MGNX), and Fulcrum Therapeutics (FULC).

How does MediciNova compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Q32 Bio has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	5.10	$29.82M	$2.66	6.08
MediciNova	$410K	156.06	-$12M	-$0.23	N/A

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Q32 Bio had 3 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Q32 Bio and 1 mentions for MediciNova. Q32 Bio's average media sentiment score of 0.40 beat MediciNova's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio currently has a consensus target price of $30.00, suggesting a potential upside of 85.64%. MediciNova has a consensus target price of $8.33, suggesting a potential upside of 541.03%. Given MediciNova's higher possible upside, analysts plainly believe MediciNova is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Q32 Bio has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Q32 Bio has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. Q32 Bio's return on equity of 149.23% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
MediciNova	-1,962.98%	-27.28%	-25.24%

Summary

Q32 Bio beats MediciNova on 12 of the 16 factors compared between the two stocks.

How does MediciNova compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and MediciNova (NASDAQ:MNOV) are related small-cap companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Niagen Bioscience has a net margin of 14.29% compared to MediciNova's net margin of -1,962.98%. Niagen Bioscience's return on equity of 22.68% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
MediciNova	-1,962.98%	-27.28%	-25.24%

Niagen Bioscience currently has a consensus target price of $10.50, suggesting a potential upside of 202.59%. MediciNova has a consensus target price of $8.33, suggesting a potential upside of 541.03%. Given MediciNova's higher probable upside, analysts plainly believe MediciNova is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Niagen Bioscience has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$130.42M	2.12	$17.38M	$0.21	16.52
MediciNova	$410K	156.06	-$12M	-$0.23	N/A

In the previous week, Niagen Bioscience had 6 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Niagen Bioscience and 1 mentions for MediciNova. Niagen Bioscience's average media sentiment score of 0.54 beat MediciNova's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Summary

Niagen Bioscience beats MediciNova on 12 of the 16 factors compared between the two stocks.

How does MediciNova compare to Artiva Biotherapeutics?

MediciNova (NASDAQ:MNOV) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

MediciNova has higher revenue and earnings than Artiva Biotherapeutics. MediciNova is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	156.06	-$12M	-$0.23	N/A
Artiva Biotherapeutics	$250K	1,094.60	-$83.86M	-$3.54	N/A

In the previous week, Artiva Biotherapeutics had 6 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 1 mentions for MediciNova. Artiva Biotherapeutics' average media sentiment score of 1.78 beat MediciNova's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

MediciNova currently has a consensus price target of $8.33, suggesting a potential upside of 541.03%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 252.30%. Given MediciNova's higher probable upside, equities research analysts plainly believe MediciNova is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Artiva Biotherapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Artiva Biotherapeutics	N/A	-73.15%	-62.74%

9.9% of MediciNova shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Artiva Biotherapeutics beats MediciNova on 9 of the 16 factors compared between the two stocks.

How does MediciNova compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

In the previous week, MacroGenics had 1 more articles in the media than MediciNova. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for MediciNova. MacroGenics' average media sentiment score of 0.67 beat MediciNova's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MacroGenics currently has a consensus price target of $5.50, indicating a potential upside of 41.03%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 541.03%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

MediciNova has lower revenue, but higher earnings than MacroGenics. MediciNova is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.66	-$74.62M	-$1.10	N/A
MediciNova	$410K	156.06	-$12M	-$0.23	N/A

MacroGenics has a net margin of -44.79% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
MediciNova	-1,962.98%	-27.28%	-25.24%

Summary

MediciNova beats MacroGenics on 9 of the 16 factors compared between the two stocks.

How does MediciNova compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Fulcrum Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MediciNova has lower revenue, but higher earnings than Fulcrum Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.62	-$74.88M	-$1.15	N/A
MediciNova	$410K	156.06	-$12M	-$0.23	N/A

Fulcrum Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. Fulcrum Therapeutics' return on equity of -25.38% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
MediciNova	-1,962.98%	-27.28%	-25.24%

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 115.79%. MediciNova has a consensus target price of $8.33, indicating a potential upside of 541.03%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 1 mentions for MediciNova. Fulcrum Therapeutics' average media sentiment score of 0.09 beat MediciNova's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fulcrum Therapeutics beats MediciNova on 9 of the 17 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$65.46M	$11.49B	$6.83B	$12.77B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	-5.65	791.61	279.15	25.53
Price / Sales	156.06	733.37	587.36	92.31
Price / Cash	N/A	71.54	72.11	49.39
Price / Book	1.53	10.85	13.06	6.11
Net Income	-$12M	$2.81B	$3.48B	$347.58M
7 Day Performance	0.78%	2.66%	3.38%	4.91%
1 Month Performance	-9.09%	-3.16%	-2.81%	-2.06%
1 Year Performance	-4.41%	190.97%	73.07%	21.03%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	1.4318 of 5 stars	$1.30 -2.3%	$8.33 +541.0%	-3.7%	$65.46M	$410K	N/A	10	High Trading Volume
QTTB Q32 Bio	4.4453 of 5 stars	$15.71 +3.3%	$30.00 +91.0%	+737.3%	$257.91M	$53.74M	5.91	39	Earnings Report
NAGE Niagen Bioscience	3.7239 of 5 stars	$3.29 +1.9%	$10.50 +219.1%	-64.0%	$257.25M	$129.42M	15.67	120	News Coverage Earnings Report
ARTV Artiva Biotherapeutics	4.2288 of 5 stars	$10.53 +2.0%	$39.00 +270.4%	+267.8%	$255.08M	$250K	N/A	81
MGNX MacroGenics	2.5241 of 5 stars	$3.85 -3.8%	$5.50 +42.9%	+137.8%	$254.25M	$157.08M	N/A	430

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. QTTB, NAGE, ARTV, MGNX, and FULC

How does MediciNova compare to Q32 Bio?

Summary

How does MediciNova compare to Niagen Bioscience?

Summary

How does MediciNova compare to Artiva Biotherapeutics?

Summary

How does MediciNova compare to MacroGenics?

Summary

How does MediciNova compare to Fulcrum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. QTTB, NAGE, ARTV, MGNX, and FULC

How does MediciNova compare to Q32 Bio?

Which has higher valuation and earnings, QTTB or MNOV?

Do insiders & institutionals hold more shares of QTTB or MNOV?

Does the media prefer QTTB or MNOV?

Do analysts prefer QTTB or MNOV?

Which has more volatility & risk, QTTB or MNOV?

Is QTTB or MNOV more profitable?

Summary

How does MediciNova compare to Niagen Bioscience?

Is NAGE or MNOV more profitable?

Do analysts rate NAGE or MNOV?

Do institutionals and insiders have more ownership in NAGE or MNOV?

Which has stronger earnings & valuation, NAGE or MNOV?

Does the media prefer NAGE or MNOV?

Which has more risk & volatility, NAGE or MNOV?

Summary

How does MediciNova compare to Artiva Biotherapeutics?

Which has better earnings and valuation, MNOV or ARTV?

Does the media refer more to MNOV or ARTV?

Which has more risk and volatility, MNOV or ARTV?

Do analysts recommend MNOV or ARTV?

Is MNOV or ARTV more profitable?

Do insiders & institutionals hold more shares of MNOV or ARTV?

Summary

How does MediciNova compare to MacroGenics?

Which has more risk & volatility, MGNX or MNOV?

Does the media prefer MGNX or MNOV?

Do insiders and institutionals have more ownership in MGNX or MNOV?

Do analysts recommend MGNX or MNOV?

Which has better earnings and valuation, MGNX or MNOV?

Is MGNX or MNOV more profitable?

Summary

How does MediciNova compare to Fulcrum Therapeutics?

Which has more risk and volatility, FULC or MNOV?

Do insiders & institutionals believe in FULC or MNOV?

Which has stronger valuation and earnings, FULC or MNOV?

Is FULC or MNOV more profitable?

Do analysts prefer FULC or MNOV?

Does the media refer more to FULC or MNOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools